Bone Marrow Transplantation最新文献

筛选
英文 中文
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. 急性髓性白血病异基因移植前可测量的残留突变 IDH1。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-06 DOI: 10.1038/s41409-024-02447-4
Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan
{"title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.","authors":"Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan","doi":"10.1038/s41409-024-02447-4","DOIUrl":"https://doi.org/10.1038/s41409-024-02447-4","url":null,"abstract":"<p><p>Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant. The prognostic implications of persistence of other common AML-associated mutations, such as IDH1, at this treatment landmark however remain incompletely defined. We performed testing for residual IDH1 variants (IDH1m) in pre-transplant CR1 blood of 148 adult patients undergoing alloHCT for IDH1-mutated AML at a CIBMTR reporting site between 2013 and 2019. No statistically significant post-transplant differences were observed between those testing IDH1m positive (n = 53, 36%) and negative pre-transplant (overall survival (OS): p = 0.4; relapse: p = 0.5). For patients with IDH1 mutated AML co-mutated with NPM1 and/or FLT3-ITD, only detection of persistent mutated NPM1 and/or FLT3-ITD was associated with significantly higher rates of relapse (p = 0.01). These data, from the largest study to date, do not support the detection of IDH1 mutation in CR1 blood prior to alloHCT as evidence of AML MRD for increased post-transplant relapse risk.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia. 与老年急性髓性白血病患者造血细胞移植存活率相关的是移植前疾病负担,而非年龄或捐献者类型。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-06 DOI: 10.1038/s41409-024-02457-2
Rui Ma, Yi Liao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Yuan-Yuan Zhang, Chen-Hua Yan, Yu-Hong Chen, Yao Chen, Jing-Zhi Wang, Feng-Rong Wang, Ting-Ting Han, Jun-Kong, Zhi-Dong Wang, Wei Han, Huan Chen, Yun He, Zheng-Li Xu, Feng-Mei Zheng, Hai-Xia Fu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun
{"title":"Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia.","authors":"Rui Ma, Yi Liao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Dong Mo, Meng Lv, Yuan-Yuan Zhang, Chen-Hua Yan, Yu-Hong Chen, Yao Chen, Jing-Zhi Wang, Feng-Rong Wang, Ting-Ting Han, Jun-Kong, Zhi-Dong Wang, Wei Han, Huan Chen, Yun He, Zheng-Li Xu, Feng-Mei Zheng, Hai-Xia Fu, Kai-Yan Liu, Xiao-Jun Huang, Yu-Qian Sun","doi":"10.1038/s41409-024-02457-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02457-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease. 类固醇难治性急性或慢性移植物抗宿主病患者细胞减少症以及早期与晚期使用鲁索利替尼治疗的影响。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-06 DOI: 10.1038/s41409-024-02445-6
Zahra Mahmoudjafari, Valkal Bhatt, John Galvin, Zhenyi Xue, Robert Zeiser, Franco Locatelli, Gérard Socié, Mohamad Mohty
{"title":"Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.","authors":"Zahra Mahmoudjafari, Valkal Bhatt, John Galvin, Zhenyi Xue, Robert Zeiser, Franco Locatelli, Gérard Socié, Mohamad Mohty","doi":"10.1038/s41409-024-02445-6","DOIUrl":"https://doi.org/10.1038/s41409-024-02445-6","url":null,"abstract":"<p><p>REACH2 and REACH3 were randomized, multicenter, open-label phase 3 studies comparing the selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib versus investigators' choice of best available therapy (BAT) in steroid-refractory (SR) acute (REACH2) or chronic (REACH3) graft-versus-host disease (aGVHD/cGVHD). Moderate-severe aGVHD/cGVHD can progress rapidly; thus, key clinical considerations driving management of patients with SR-aGVHD/SR-cGVHD are prompt treatment initiation and concomitant cytopenias. These post hoc analyses of REACH2/REACH3 describe the impact of timing of treatment initiation after SR-aGVHD/SR-cGVHD diagnosis and development of concomitant cytopenias on treatment outcomes. Ruxolitinib initiation within 3 days from SR-aGVHD diagnosis yielded an extended duration of response and higher Day 28 complete response rates compared with initiation ≥7 days after SR-aGVHD diagnosis (median 178 vs 167 days and 36.6% vs 25.0%, respectively). For patients with SR-cGVHD, Week 24 overall response was not impacted by time to treatment (54.5% vs 42.6% for <14 vs >28 days). Clinically relevant cytopenias were manageable, allowing for maintenance of dose intensity (median 20 mg/d), and did not impact the favorable efficacy outcomes from ruxolitinib treatment. This analysis highlights the practical importance of considering earlier ruxolitinib initiation after SR diagnosis in GVHD and the benefits of ruxolitinib treatment compared with BAT even for patients with cytopenias.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data. 与临床试验数据相比,对 MDS 患者进行异体肝细胞移植前曲硫安治疗的实际效果分析。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-05 DOI: 10.1038/s41409-024-02456-3
Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schroeder, Miroslaw Markiewicz, Hélène Labussiere-Wallet, Péter Reményi, Fabio Ciceri, Imran Khan, Uwe Pichlmeier, Xieran Li, Friedrich Stölzel
{"title":"Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data.","authors":"Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schroeder, Miroslaw Markiewicz, Hélène Labussiere-Wallet, Péter Reményi, Fabio Ciceri, Imran Khan, Uwe Pichlmeier, Xieran Li, Friedrich Stölzel","doi":"10.1038/s41409-024-02456-3","DOIUrl":"https://doi.org/10.1038/s41409-024-02456-3","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT). 更正:沙特阿拉伯王国造血细胞移植和细胞治疗活动情况调查;沙特血液和骨髓移植协会 (SSBMT) 的报告。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-04 DOI: 10.1038/s41409-024-02450-9
{"title":"Correction: Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT).","authors":"","doi":"10.1038/s41409-024-02450-9","DOIUrl":"https://doi.org/10.1038/s41409-024-02450-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mold infections in chronic granulomatous disease patients-what comes to the rescue? 慢性肉芽肿病患者的霉菌感染--如何拯救?
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-04 DOI: 10.1038/s41409-024-02342-y
Horst von Bernuth, Tayfun Güngör
{"title":"Mold infections in chronic granulomatous disease patients-what comes to the rescue?","authors":"Horst von Bernuth, Tayfun Güngör","doi":"10.1038/s41409-024-02342-y","DOIUrl":"10.1038/s41409-024-02342-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease. 慢性肉芽肿病患者在霉菌感染情况下进行造血细胞移植的结果。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-11-04 DOI: 10.1038/s41409-024-02389-x
Ahnika Kline, Mark Parta, Jennifer Cuellar-Rodriguez, Juan Gea-Banacloche, Corin Kelly, Stefania Pittaluga, Christa S Zerbe, Steven M Holland, Harry L Malech, Elizabeth M Kang
{"title":"Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease.","authors":"Ahnika Kline, Mark Parta, Jennifer Cuellar-Rodriguez, Juan Gea-Banacloche, Corin Kelly, Stefania Pittaluga, Christa S Zerbe, Steven M Holland, Harry L Malech, Elizabeth M Kang","doi":"10.1038/s41409-024-02389-x","DOIUrl":"10.1038/s41409-024-02389-x","url":null,"abstract":"<p><p>Chronic granulomatous disease (CGD) is a disorder of immunity characterized by phagocyte dysfunction. Mold infections in patients with CGD are often severe and disseminated. We present patient characteristics, microbiological data, and outcomes for 26 patients with CGD who received hematopoietic cell transplantation (HCT) or gene therapy-modified cells (GT) between 2008 and 2019, with proven fungal infection either before or during their transplant. All patients engrafted, and all but one GT recipient had neutrophil recovery and evidence of functional correction. Eighteen patients (69%) are currently alive and 19 patients (73% of total, 90% of patients with repeat imaging performed) had evidence of radiographic improvement. With 3 exceptions, deaths were not principally related to the fungal infection and duration of antecedent infection did not correlate with death. Aspergillus species accounted for the majority of disease (50%), followed by Phellinus species (18%). Osteomyelitis and disseminated disease were common, as only 11 patients (42%) had disease restricted to pneumonia. Triazole therapy was used in all 26 patients, with combination therapy used in 25 (96%). HCT or gene therapy, with appropriate antifungal therapy, are viable therapies for refractory fungal infections in patients with CGD.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. 多发性骨髓瘤自体移植(Auto-HCT)后与治疗相关的急性白血病的特征和预后。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-30 DOI: 10.1038/s41409-024-02455-4
Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman, Edward Stadtmauer
{"title":"Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.","authors":"Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman, Edward Stadtmauer","doi":"10.1038/s41409-024-02455-4","DOIUrl":"https://doi.org/10.1038/s41409-024-02455-4","url":null,"abstract":"<p><p>With a prolonging duration of survivorship, patients with multiple myeloma (MM) who receive high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) have an increased risk of secondary malignancy, most concerning acute leukemia. We retrospectively reviewed the records of all patients with MM who underwent auto-HCT between January 1, 2010, and January 1, 2023, who later developed therapy-related acute leukemia (t-AL). Of 1770 patients with MM who underwent auto-HCT, 18 (1.01%) developed t-AL at a mean interval of 60.0 ± 41.3 months after auto-HCT. The patients with t-AL consisted of 9 (50%) with B-cell acute lymphoblastic leukemia (B-ALL), 8 (44.4%) with acute myeloid leukemia (AML), and 1 (5.6%) with acute promyelocytic leukemia (APML). All patients had received an alkylating agent as part of induction, and the majority received lenalidomide as maintenance therapy. Genetic abnormalities of t-AL were consistent with prior reports. Median overall survival from diagnosis of t-AL was 19.5 months. In patients with t-AL who entered CR, long term survival was common. Further research on predisposing conditions to developing t-AL in patients with MM undergoing auto-HCT is warranted.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. 急性髓性白血病异基因移植前可测量的残留突变 IDH2。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-25 DOI: 10.1038/s41409-024-02449-2
Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan
{"title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.","authors":"Gege Gui, Niveditha Ravindra, Pranay S Hegde, Georgia Andrew, Devdeep Mukherjee, Zoë Wong, Jeffery J Auletta, Firas El Chaer, Evan C Chen, Yi-Bin Chen, Adam Corner, Steven M Devine, Sunil G Iyer, Antonio Martin Jimenez Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Laura W Dillon, Christopher S Hourigan","doi":"10.1038/s41409-024-02449-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02449-2","url":null,"abstract":"<p><p>Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined. A nationwide cohort of 257 adult patients in first remission (CR1) from AML associated with an IDH2 mutation (IDH2m) undergoing allogeneic transplant during the period 2013-2019 in the United States had rates of relapse and survival three years after transplantation of 24% and 71%, respectively. Pre-transplant clinical flow cytometry assessment was not useful in stratifying patients based on risk of post-transplant relapse or death. DNA-sequencing was performed on CR1 blood collected within 100 days before transplant. Persistent detection of IDH2m was common (51%) and associated with increased relapse and death compared to testing negative. Co-mutation at initial diagnosis with mutated NPM1 and/or FLT3-ITD was common in this cohort (41%) and use of these validated MRD markers provided superior stratification compared to IDH2m testing. Patients testing negative for IDH2m prior to transplant had low relapse-related death, regardless of conditioning intensity. Post-transplant relapse rates for those with persistently detectable IDH2m in pre-transplant remission were lower after the FDA approval of enasidenib in August 2017.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT. 欧洲 CAR T 细胞治疗 DLBCL 和 PMBCL 后的严重 ICANS 以及使用左乙拉西坦预防癫痫发作的评估:代表 EBMT 细胞治疗与免疫生物学工作组 (CTIWP) 进行的调查。
IF 4.5 2区 医学
Bone Marrow Transplantation Pub Date : 2024-10-25 DOI: 10.1038/s41409-024-02451-8
Piera Angelillo, Ana Alarcon Tomas, Edoardo Campodonico, Urban Novak, Ludovic Gabellier, Igor Wolfgang Blau, Mi Kwon, Ron Ram, Edouard Forcade, Caroline Besley, Vladan Vucinic, Nicolaus Kröger, Lucía López Corral, Jan Vydra, Silvia Ferrari, Bastian von Tresckow, Marie Therese Rubio, Rafael Hernani, Simona Sica, Friedrich Stölzel, Montserrat Rovira, Eva Wagner-Drouet, Jose Antonio Pérez-Simón, Cristina Castilla-Llorente, Andres J M Ferreri, Jorinde D Hoogenboom, Isabel Sanchez Ortega, Florent Malard, Jürgen Kuball, Annalisa Ruggeri
{"title":"Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.","authors":"Piera Angelillo, Ana Alarcon Tomas, Edoardo Campodonico, Urban Novak, Ludovic Gabellier, Igor Wolfgang Blau, Mi Kwon, Ron Ram, Edouard Forcade, Caroline Besley, Vladan Vucinic, Nicolaus Kröger, Lucía López Corral, Jan Vydra, Silvia Ferrari, Bastian von Tresckow, Marie Therese Rubio, Rafael Hernani, Simona Sica, Friedrich Stölzel, Montserrat Rovira, Eva Wagner-Drouet, Jose Antonio Pérez-Simón, Cristina Castilla-Llorente, Andres J M Ferreri, Jorinde D Hoogenboom, Isabel Sanchez Ortega, Florent Malard, Jürgen Kuball, Annalisa Ruggeri","doi":"10.1038/s41409-024-02451-8","DOIUrl":"https://doi.org/10.1038/s41409-024-02451-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信